CytoDyn (CYDY) Short term Debt (2011 - 2025)
CytoDyn's (CYDY) quarterly Short term Debt came in at $27.2 million in Q4 2025, down 4.67% YoY from $28.5 million in Q4 2024, and little changed on a QoQ basis from $27.2 million in Q3 2025.
CytoDyn (CYDY) Short term Debt (2011 - 2025) Analysis & Trends
CytoDyn (CYDY) has 10 years of Short term Debt data on file, last reported at $27.2 million in Q4 2025.
- Quarterly Short term Debt fell 4.67% year-over-year to $27.2 million in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $27.2 million (down 4.67% YoY) and the FY2025 annual result came in at $27.2 million, down 8.7% from the prior year.
- Short term Debt held at $27.2 million in Q4 2025, from $27.2 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $62.7 million in Q2 2021 to a low of $27.1 million in Q1 2025.
- A 5-year average of $35.2 million and a median of $33.8 million in 2023 frame the typical range for Short term Debt.
- Annual changes were most pronounced in 2021 — Short term Debt surged 830.27% — and 2022, when it sank 42.24%.
- Tracing CYDY's Short term Debt over 5 years: stood at $43.9 million in 2021, then fell by 15.96% to $36.9 million in 2022, then dropped by 10.88% to $32.9 million in 2023, then decreased by 13.32% to $28.5 million in 2024, then retreated by 4.67% to $27.2 million in 2025.
- The last three Short term Debt figures came in at $27.2 million (Q4 2025), $27.2 million (Q3 2025), and $27.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 27.20 Mn |
| Aug 31, 2025 | 27.20 Mn |
| May 31, 2025 | 27.20 Mn |
| Feb 28, 2025 | 27.14 Mn |
| Nov 30, 2024 | 28.53 Mn |
| Aug 31, 2024 | 28.92 Mn |
| May 31, 2024 | 29.79 Mn |
| Feb 29, 2024 | 30.17 Mn |
| Nov 30, 2023 | 32.91 Mn |
| Aug 31, 2023 | 33.10 Mn |
| May 31, 2023 | 34.42 Mn |
| Feb 28, 2023 | 36.01 Mn |
| Nov 30, 2022 | 36.93 Mn |
| Aug 31, 2022 | 36.83 Mn |
| May 31, 2022 | 36.24 Mn |
| Feb 28, 2022 | 35.65 Mn |
| Nov 30, 2021 | 43.95 Mn |
| Aug 31, 2021 | 51.33 Mn |
| May 31, 2021 | 62.75 Mn |
| Feb 28, 2021 | 37.98 Mn |